前列腺癌肝转移的临床基因组学特征
该研究分析公共靶向测序数据中已知转移部位的前列腺癌患者临床与基因组数据,发现肝转移较其他部位转移死亡风险更高(HR:3.96,95%CI:2.4-6.5,p<0.0001),且肝转移组织富集MYC扩增(29.5% vs. 9.8%,FDR=0.001)、PTEN缺失(42% vs. 20.8%,FDR=0.005)和PIK3CB扩增(8.2% vs. 0.9,FDR=0.005)。
要点
- 前列腺癌肝转移患者死亡风险显著高于其他部位转移(HR:3.96,95%CI:2.4-6.5,p<0.0001)。
- 肝转移组织较其他转移部位更富集MYC扩增(29.5% vs. 9.8%,FDR=0.001)和PTEN缺失(42% vs. 20.8%,FDR=0.005)。
- 肝转移组织较其他转移部位更富集PIK3CB扩增(8.2% vs. 0.9,FDR=0.005),未见与肝转移显著相关的点突变。
核心结论
- 前列腺癌肝转移与较差生存及侵袭性基因组特征相关,包括MYC扩增、PTEN缺失和PIK3CB扩增。
- 这些发现可能对预后、治疗和临床试验有启示。
研究设计与样本
- 分析来自公共靶向测序数据中已知转移部位的前列腺癌转移患者临床与基因组数据。
主要发现
- 前列腺癌肝转移较其他部位转移赋予高死亡风险(HR:3.96,95%CI:2.4-6.5,p<0.0001)。
- 肝转移组织较其他转移部位更富集MYC扩增(29.5% vs. 9.8%,FDR=0.001)。
- 肝转移组织较其他转移部位更富集PTEN缺失(42% vs. 20.8%,FDR=0.005)。
- 肝转移组织较其他转移部位更富集PIK3CB扩增(8.2% vs. 0.9,FDR=0.005)。
- 与其他转移部位相比,未发现与肝转移显著相关的点突变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The site of prostate cancer metastasis is an important predictor of oncologic outcomes, however, the clinicogenomic characteristics associated with the site are not well-defined. Herein, we characterize the genomic alterations associated with the metastatic site of prostate cancer. METHODS: We analyzed clinical and genomic data from prostate cancer patients with metastatic disease and known metastatic sites from publicly available targeted sequencing data. RESULTS: Prostate cancer metastasis to the liver versus other sites of metastasis conferred a high hazard for death in patients with metastatic prostate cancer (HR: 3.96, 95% CI: 2.4-6.5, p < 0.0001). Genomic analysis of metastatic tissues of prostate cancer-specific genes demonstrated that liver metastases were more enriched with MYC amplification (29.5% vs. 9.8%, FDR = 0.001), PTEN deletion (42% vs. 20.8%, FDR = 0.005), and PIK3CB amplification (8.2% vs. 0.9, FDR = 0.005) compared to other sites. No point mutations were significantly associated with liver metastasis compared to other metastatic sites. CONCLUSION: Liver metastases in prostate cancer are associated with poor survival and aggressive genomic features, including MYC-amplification, PTEN-deletion, and PIK3CB-amplification. These findings could have prognostic, treatment, and trial implications.
引用
- Alshalalfa M, Seldon C, Franco I, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer Prostatic Dis. 2022. PMID: 35022600. doi:10.1038/s41391-021-00486-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。